Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.73 -7.5%	$1.64	$0.51 ▼ $2.86	$96.40M	-0.09	113,766 shs	76,187 shs
CRBP Corbus Pharmaceuticals	$10.03 +1.4%	$8.61	$4.64 ▼ $61.72	$122.97M	3.2	184,516 shs	111,522 shs
MIRA MIRA Pharmaceuticals	$1.39 -2.1%	$1.44	$0.73 ▼ $2.56	$26.51M	1.77	1.08 million shs	167,074 shs
ZURA Zura Bio	$2.03 -1.0%	$1.44	$0.97 ▼ $5.07	$131.99M	-0.06	514,510 shs	223,413 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	+2.19%	-2.60%	-15.77%	+148.94%	+82.96%
CRBP Corbus Pharmaceuticals	+1.02%	+6.92%	+6.80%	+34.38%	-83.43%
MIRA MIRA Pharmaceuticals	-0.70%	-4.05%	-17.92%	+12.70%	-23.24%
ZURA Zura Bio	+1.99%	+17.82%	+25.00%	+105.00%	-42.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTB Connect Biopharma	3.5559 of 5 stars	3.8	5.0	0.0	3.4	2.5	0.0
CRBP Corbus Pharmaceuticals	4.4784 of 5 stars	3.6	3.0	4.7	3.0	2.5	0.6
MIRA MIRA Pharmaceuticals	2.986 of 5 stars	3.8	5.0	0.0	2.2	0.0	0.6
ZURA Zura Bio	3.52 of 5 stars	3.5	5.0	0.0	1.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	3.50	Strong Buy	$7.00	304.62% Upside
CRBP Corbus Pharmaceuticals	3.10	Buy	$49.00	388.53% Upside
MIRA MIRA Pharmaceuticals	3.50	Strong Buy	$17.00	1,123.02% Upside
ZURA Zura Bio	3.00	Buy	$14.00	589.66% Upside

Current Analyst Ratings Breakdown

Latest MIRA, CNTB, ZURA, and CRBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$3.00 ➝ $2.00
8/15/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $16.00
8/15/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/13/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/6/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $53.00
7/30/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$28.00
7/22/2025	CNTB Connect Biopharma	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/12/2025	CRBP Corbus Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/12/2025	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$7.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$1.97M	49.06	N/A	N/A	$1.67 per share	1.04
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$11.69 per share	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.13 per share	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$15.63M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/5/2025 (Estimated)
CRBP Corbus Pharmaceuticals	-$40.21M	-$4.76	N/A	N/A	N/A	N/A	-43.65%	-39.62%	11/6/2025 (Estimated)
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.49	N/A	N/A	N/A	N/A	-406.70%	-328.44%	11/11/2025 (Estimated)
ZURA Zura Bio	-$45.39M	-$0.70	N/A	N/A	N/A	N/A	-49.11%	-40.06%	11/6/2025 (Estimated)

Latest MIRA, CNTB, ZURA, and CRBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	H1 2025	CNTB Connect Biopharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/14/2025	Q2 2025	MIRA MIRA Pharmaceuticals	-$0.11	-$0.09	+$0.02	-$0.09	N/A	N/A
8/14/2025	Q2 2025	ZURA Zura Bio	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
8/5/2025	Q2 2025	CRBP Corbus Pharmaceuticals	-$1.55	-$1.44	+$0.11	-$1.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	7.24	7.24
CRBP Corbus Pharmaceuticals	N/A	9.21	9.21
MIRA MIRA Pharmaceuticals	N/A	2.80	2.80
ZURA Zura Bio	N/A	8.40	8.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
CRBP Corbus Pharmaceuticals	64.64%
MIRA MIRA Pharmaceuticals	35.16%
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
CRBP Corbus Pharmaceuticals	4.00%
MIRA MIRA Pharmaceuticals	6.65%
ZURA Zura Bio	22.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	110	55.72 million	43.13 million	Optionable
CRBP Corbus Pharmaceuticals	40	12.26 million	11.77 million	Optionable
MIRA MIRA Pharmaceuticals	2	19.07 million	17.80 million	Not Optionable
ZURA Zura Bio	3	65.02 million	50.65 million	Optionable

MIRA, CNTB, ZURA, and CRBP Headlines

Recent News About These Companies

FY2025 EPS Estimates for Zura Bio Boosted by HC Wainwright

August 23 at 7:45 AM | marketbeat.com

FY2025 EPS Estimates for Zura Bio Lifted by HC Wainwright

August 23 at 2:45 AM | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Given New $2.00 Price Target at HC Wainwright

August 21, 2025 | marketbeat.com

HC Wainwright Issues Pessimistic Forecast for Zura Bio (NASDAQ:ZURA) Stock Price

August 21, 2025 | americanbankingnews.com

Zura Bio price target lowered to $2 from $3 at H.C. Wainwright

August 19, 2025 | msn.com

Q1 Earnings Estimate for Zura Bio Issued By Leerink Partnrs

August 19, 2025 | marketbeat.com

Oppenheimer Has Lowered Expectations for Zura Bio (NASDAQ:ZURA) Stock Price

August 18, 2025 | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Price Target Cut to $16.00 by Analysts at Oppenheimer

August 17, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Earns Buy Rating from Chardan Capital

August 17, 2025 | marketbeat.com

Zura Bio's (ZURA) Buy Rating Reiterated at Chardan Capital

August 17, 2025 | americanbankingnews.com

Zura Bio (NASDAQ:ZURA) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS

August 16, 2025 | marketbeat.com

Zura Bio price target lowered to $16 from $17 at Oppenheimer

August 15, 2025 | msn.com

Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates

August 14, 2025 | businesswire.com

Zura Bio Limited (NASDAQ:ZURA) Receives Average Recommendation of "Buy" from Brokerages

August 7, 2025 | marketbeat.com

Zura Bio (ZURA) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Zura Bio (NASDAQ:ZURA) Shares Up 7.5% - What's Next?

August 6, 2025 | marketbeat.com

Robert Lisicki on Living Up to Zura Bio’s Heroic Namesake

July 31, 2025 | pharmexec.comP

3 Penny Stocks With Market Caps Over $70M Worth Watching

July 18, 2025 | finance.yahoo.com

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 18, 2025 | finance.yahoo.com

Zura Bio Announces Chief Financial Officer Transition

July 1, 2025 | businesswire.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MIRA, CNTB, ZURA, and CRBP Company Descriptions

Connect Biopharma NASDAQ:CNTB

$1.73 -0.14 (-7.49%)

Closing price 04:00 PM Eastern

Extended Trading

$1.72 -0.01 (-0.58%)

As of 04:10 PM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Corbus Pharmaceuticals NASDAQ:CRBP

$10.03 +0.14 (+1.42%)

Closing price 04:00 PM Eastern

Extended Trading

$9.99 -0.04 (-0.35%)

As of 05:06 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.39 -0.03 (-2.11%)

Closing price 04:00 PM Eastern

Extended Trading

$1.40 +0.02 (+1.08%)

As of 04:39 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Zura Bio NASDAQ:ZURA

$2.03 -0.02 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 +0.01 (+0.49%)

As of 04:57 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time